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ABSTRACT 
 
Introduction: Tuberculosis (TB) control is included in the eight Millennium 
Development Goals, with the aim to halve the prevalence and death rate associated 
with TB by 2015 compared to 1990. TB is a global public health crisis aggravated by 
the emergence of multidrug-resistance (MDR) and extensively drug-resistance 
(XDR). South Africa is currently ranked as the country with the third highest TB and 
fifth highest MDR-TB burden in the world. Sizwe Hospital is the only specialised TB 
hospital in the Gauteng Province, responsible for the management of MDR and 
XDR-TB. The number of admissions has increased since 2007, poor outcomes 
were reported, the treatment is expensive and patients stay for long periods in 
hospital. Risk factors and MDR-TB outcomes have not been well described in South 
Africa. Information on admission trends, demographic and clinical profiles as well as 
treatment outcomes are lacking and is critical to evaluate and strengthen the 
management of MDR and XDR-TB at Sizwe Hospital. 
Aim: The aim of the study is to describe and compare the admission trends and 
treatment outcomes of MDR and XDR-TB patients at Sizwe Hospital in Gauteng 
Province for the period January 2008 to December 2009. 
Methodology: The study design was an analytical cross-sectional study based on a 
record review of all adult MDR and XDR-TB patients admitted at Sizwe Hospital. 
Information was extracted from the medical records and drug-resistant registers. 
Excel and Epi-info was used to record and analyse the data respectively. The 
variables: admissions, demographic profile, clinical profile and treatment outcomes, 
were analysed through descriptive statistics and statistical tests were used for the 
comparison analysis. Logistic regression was performed to determine factors 
influencing death. Ethical approval was obtained from the Human Research Ethics 
Committee (Medical) of the University of the Witwatersrand. 
Results: The total number of adult admissions for the period was 891 with an 
increased admission over the two years. MDR-TB accounted for 95.3% (849) of the 
admissions and XDR-TB for 4.7% (42). The male admissions were higher (55.8%) 
than the female admissions in both years. The majority of patients were in the age 
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group 28-32 years. The median age was 36 years and increased from 35 years to 
36.5 years over the study period. Most patients (75.9%, n=676), had a previous 
history of TB and a higher proportion of XDR-TB patients (95.2%, n=40) had a 
history of previous TB. A high proportion of 74.9% (655) of patients were HIV 
positive, with a higher proportion in females (81.5%, n=317) as compared to males 
(69.5%, n=338). Culture conversion decreased from 80.8% (308) to 76.7% (391) 
over the two years and was higher (79.2%, n=672) in MDR-TB compared to XDR-
TB (64.3%, n=27). No statistical significance was found in the treatment outcomes 
comparing HIV positive and negative patients. Low cure (2.4%) was achieved and 
treatment completed decreased from 42% (160) to 13.5% (69), when comparing 
2008 figures with 2009, as a result of a  higher proportion (33.3%, n=170) of 
patients still on treatment in 2009. Age, TB diagnosis and HIV were significantly 
associated with death. 
Discussion: The majority of admissions were males, between 28-32 years of age 
who were MDR-TB patients for the study periods January 2008 to December 2009. 
The increase in the number of admissions over the study period was not significant, 
however could be due to non adherence of TB treatment. XDR-TB was significantly 
(p<0.01) associated with a previous history of TB treatment and female gender with 
HIV infection (p<0.0001). High culture conversion was achieved in both years as a 
result of monitoring and support while in hospital. HIV infection did not influence 
treatment outcomes. Low cure however was observed mostly due to the lack of 
documented culture results from the clinics. The decrease in treatment success 
over the two years might be due to high default rate after discharge from hospital, 
increase in mortality and being still on treatment during the study period. Risk 
factors associated with the high mortality were age, HIV and XDR-TB.  
Conclusions: The study identified the need for a comprehensive integrated 
HIV/AIDS care. Hospitalisation contributed to early success and an intervention 
is needed to strengthen TB control management from prevention and early 
detection to case holding and follow up to improve community care. Further 
studies are necessary to identify risk factors for deaths and treatment default. 
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GLOSSARY OF TERMS  
 
Drug-resistant TB is a disease (usually pulmonary) caused by Mycobacterium 
tuberculosis strains resistant to one or more anti-TB drugs (NDOH, 2011). 
MDR-TB is defined as resistance to rifampicin and isoniazid, with or without 
resistance to other first-line anti-TB drugs (NDOH, 2011). 
XDR-TB is defined as resistance to rifampicin, isoniazid, any fluoroquinolone and 
resistance to one or more of the following injectable anti-TB drugs: kanamycin, 
amikacin, capreomycin (NDOH, 2011). 
Interim treatment outcome: Outcome recorded at the end of hospitalization. (Note 
that this definition is specific for the study to evaluate hospital outcomes). 
Still in hospital: Interim treatment outcome when a patient was not discharged 
from hospital as on the 31th of May 2011. (Note that this definition is specific for the 
study as patients were followed up as per approved protocol until this date). 
Culture conversion: A negative culture result on discharge from hospital. (Note 
that this definition is specific for the study as interim outcome was documented at 
the end of hospitalisation). 
Treatment outcome: Outcome as on 31st May 2011. (Note that this definition is 
specific for the study as patients were followed up as per approved protocol until 
this date). 
Treatment outcome definitions: The outcome definitions are based on 
bacteriological culture as a monitoring tool: 
· Cure: A patient who has completed treatment and has been consistently 
culture-negative for five consecutive months in the final twelve months of 
treatment. If one positive culture is reported during that time and there is no 
concomitant clinical evidence of deterioration, a patient may still be 
considered cured, provided that this positive culture is followed by a 
minimum of three consecutive negative cultures, taken at least thirty days 
apart (NDOH, 2011). 
· Treatment completed: A patient who has completed treatment but does not 
meet the definition for cure due to lack of bacteriologic results (i.e. less than 
xiii 
 
five cultures were performed in the final twelve months of treatment) (NDOH, 
2011). 
· Treatment failure: A patient who has had two or more of the five 
consecutive cultures taken in the final twelve months which are positive, or if 
any one of the final three cultures are positive (NDOH, 2011). 
· Death: A patient who dies from any cause while on DR-TB treatment 
(NDOH, 2011). 
· Treatment default: A patient who interrupts DR-TB treatment for two or 
more consecutive months for any reason (NDOH, 2011). 
· Transfer out: A patient who has been transferred to a reporting unit in 
another province and for whom the treatment outcome is unknown (NDOH, 
2011). 
· Still on treatment: A patient who for any reason is still on treatment at the 
time of submission of treatment outcome report (NDOH, 2011). 
· Successful treatment completed: Cure and treatment completed combined 
(NDOH, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
LIST OF ABBREVIATIONS 
 
AIDS 
 
Acquired Immune Deficiency Syndrome 
 
ART Antiretroviral Therapy 
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WHO 
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CHAPTER 1 
INTRODUCTION 
 
This chapter will cover the background to the study, statement of the problem and 
the aims and objectives will de defined. 
 
1.1      BACKGROUND 
 
Tuberculosis (TB) control is included in the eight Millennium Development Goals, 
with the aim to halve the prevalence and death rate associated with TB by 2015 
compared to 1990 (World Health Organization, 2010). Tuberculosis was declared a 
global emergency by the World Health Organization (WHO) in April 1993 (WHO, 
2003). TB remains a worldwide health crisis and the leading cause of death among 
people living with HIV/AIDS (Small, 2009). According to the WHO there were an 
estimated 9.4 million new TB cases in 2008 with 1.8 million deaths (WHO, 2010). 
South Africa (SA) has the third highest TB burden and the fifth highest burden of 
multidrug- resistant (MDR) TB in the world (National Department of Health, 2011). 
The emergence of drug-resistant (DR) TB is an additional major threat to public 
health worldwide, with 440 000 MDR-TB cases reported in 2008, of which a third of 
these patients died (WHO, 2010). Extensively Drug-resistant (XDR) TB is a growing 
public health problem worldwide associated with high mortality (Raviglione & Smith, 
2007). MDR-TB is defined as resistance to at least two powerful drugs, rifampicin 
and isoniazid. XDR-TB is a huge concern since resistance exists for the same drugs 
with additional resistance to the fluoroquinolones and one or more injectables 
(amikacin, kanamycin or capreomycin). Both these forms of TB are difficult and 
expensive to treat (National Department of Health, 2011).  
 
Sizwe Hospital is a specialised TB hospital responsible for the management of MDR 
and XDR-TB. The Hospital is situated in Gauteng Province and has 266 approved 
beds. All diagnosed, laboratory confirmed cases in the province are referred and 
admitted at Sizwe Hospital, and discharged only after a negative culture result. The 
 - 2 -
patients are discharged and provided with hospital transport to the clinic nearest to 
their home to continue treatment under supervision. Patients come for follow up with 
organized transport to the hospital on a monthly to three monthly bases and have to 
bring their culture results to monitor progress. The hospital provides the treatment 
and is also responsible for keeping the drug-resistant register. .  
 
 MDR-TB patients were treated mainly with the standardised regimen consisting of 
at least six months intensive phase with kanamycin, pyrazinamide, ofloxacin, 
ethionamide and terizidone or ethambutol, followed by eighteen months 
continuation phase after culture conversion, with ofloxacin, ethionamide and 
terizidone or ethambutol.  XDR-TB patients were treated with at least four to seven 
drugs expected to be effective (capreomycin, ofloxacin later substituted with 
moxifloxacin, ethionamide, terizidone, pyrazinamide, high dose isoniazid, p-
aminosalicylic acid, clarithromycin, clofazimine, azithromycin and amoxicillin-
clavulanate) for eighteen to twenty four months (National Department of Health, 
2010). One hundred and eleven XDR-TB patients have been admitted since the 
emergence of the disease late in 2006 until 2010. Almost one thousand nine 
hundred MDR-TB cases have been admitted from 2007 to 2010 according to the 
drug-resistant registers at Sizwe Hospital (Gauteng Department of Health, 2011). 
 
The management of MDR and XDR-TB in South Africa is in accordance with the 
National Tuberculosis Control Programme guidelines and Directly Observed 
Therapy Short course (DOTS) expansion and enhancement strategy. A 
decentralized MDR-TB management approach has been incorporated in the 
updated National guidelines as a policy framework. Decentralisation of MDR-TB 
management is a community-based treatment model providing for shorter 
hospitalization and includes the management of DR-TB in decentralized MDR-TB 
units, satellite MDR-TB units, or in the community primary health care clinics, 
mobile MDR-TB injection teams and/or community health care workers and 
households (National Department of Health, 2011). 
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1.2 PROBLEM STATEMENT  
  
According to Wood, Lawn, Johnstone-Robertson, et al. (2011), TB control in South 
Africa has failed and it is time to reappraise its strategy. Drug-resistant TB is a 
growing epidemic with high mortality, requiring expensive treatment. The number of 
admissions at Sizwe hospital has increased over the past years since 2007, the 
length of stay in hospital is long with an average of four months, the cost of 
treatment increased and poor treatment outcomes were reported (Gauteng 
Department of Health, 2011). Information on MDR and XDR-TB admission trends, 
demographic and clinical profiles as well as treatment outcomes are lacking and is 
critical to understand the admission patterns as well as to measure and evaluate 
treatment outcomes for effective MDR and XDR-TB management . 
 
1.3 JUSTIFICATION FOR THE STUDY 
 
Limited studies were conducted on MDR and XDR-TB treatment outcomes in South 
Africa and risk factors such as the impact of HIV and outcomes of MDR-TB 
treatment, have not been well described (Farley, Ram, Pam, et al., 2011). Studies 
that have investigated trends and outcomes of MDR-TB in Sizwe Hospital are 
lacking. As the only specialized TB Hospital in Gauteng Province, expert 
management and advice should be based on accurate information. 
 
This research therefore attempts to analyse the differences in the caseload, 
demographic and clinical profiles as well as treatment outcomes for two years at 
Sizwe Hospital. This information could assist Hospital management, TB control 
programmes of National and Provincial Departments of Health and senior 
management of other specialised TB institutions to strengthen MDR and XDR-TB 
management and control.  
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1.4 RESEARCH QUESTION 
 
This study aimed to describe and compare the difference in admission trends and 
treatment outcomes between MDR and XDR-TB patients at Sizwe Hospital in 
Gauteng Province, for the period January 2008 to December 2009. 
 
1.5      AIM AND OBJECTIVES 
 
1.5.1        AIM 
 
The aim of the study is to describe and compare the admission trends and treatment 
outcomes of MDR and XDR-TB patients at Sizwe Hospital in Gauteng Province, for the 
period January 2008 to December 2009.  
 
1.5.2        OBJECTIVES  
 
The objectives are as follows: 
· To describe and compare admission trends for MDR and XDR-TB in 
Sizwe Hospital for the study period January 2008 to December 2009. 
· To describe and compare demographics of these patients between the 
periods January to December 2008 and January to December 2009. 
·    To determine changes in treatment outcomes for these patients for the 
study period. 
 
 
 
 
 
 
 
 
- 5 - 
 
CHAPTER 2 
LITERATURE REVIEW 
 
In this chapter, relevant literatures on MDR and XDR-TB in South Africa and 
worldwide are discussed.  
 
2.1 DISTRIBUTION OF DISEASE 
 
Increasing numbers of cases of drug-resistant TB, as stated by Jassal and Bishai, 
2009, is due to inadequate regimens and non adherence to therapy. Several 
epidemiological factors such as HIV infection and inadequate case detection and 
treatment completion have contributed to the increase in XDR-TB (Jassal & Bishai, 
2009). This necessitates a comprehensive, universal approach that can reverse the 
current trends of drug resistance. 
 
2.1.1       MDR-TB WORLDWIDE 
 
The burden of MDR-TB disease varies significantly from country to country and 
region to region (Dias-Baptista, Uso, Marcondes- Machado, 2008). MDR-TB 
prevalence of 7.9% (361) was found in a study done by Migliori, Besozzi, Girardi 
et al. (2007) from cases analysed in Estonia, Germany, Italy and the Russian 
Federation, and 16.9% (196) MDR-TB prevalence was found in another study by 
Kliiman and Altraja (2009) only in Estonia.  According to the WHO (2010), 3.6% 
(440,000) of TB cases globally in 2008 were estimated to have MDR-TB with 
cases documented in nearly 90 countries and regions worldwide. The highest 
prevalence of cases was reported in Asia, which contributes 50% of the global 
burden of MDR-TB (WHO, 2010). Worldwide the proportion of MDR-TB reported 
to the WHO, ranges from 0% to 28.3% among new TB cases. The highest 
proportions of MDR-TB ever documented were from Russia ranging from 23.8% 
to 28.3%; Tajikistan, with 61.6% MDR-TB among previously treated TB patients 
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in Dushanbe city and Rudaki district (WHO, 2010). China reported 5.7% among 
new cases and 25.6% among those previously treated (WHO, 2010). 
 
2.1.2       WORLDWIDE XDR-TB 
 
XDR-TB was reported in fifty nine countries and confirms that this is a global 
public health threat (Sotgiu, Ferrara, Matteelli, et al., 2009). WHO estimates 
40,000 annual XDR-TB cases with many cases still unreported and 772 cases 
reported from 28 countries in 2007. Surveillance data on testing for XDR-TB from 
46 countries found that 5.4% of MDR-TB cases were XDR-TB (WHO, 2008). The 
Centers for Disease Control (CDC) and the WHO surveyed an international 
network of TB laboratories during 2000–2004 and of 17,690 TB isolates, 2% 
were XDR. In addition, population-based MDR-TB data were obtained from the 
United States (1993–2004), Latvia (2000–2002), and South Korea (2004). In 
these cases it was found that 4%, 19%, and 15% respectively, were XDR (CDC, 
2006). Kim, Kim, Park, et al. (2008) and Mitnick, Shin, Sueng, et al. (2008), found 
that 5.3% and 7.4% of TB cases were XDR in South Korea and Peru 
respectively. 
 
2.1.3         TB DRUG RESISTANCE IN SA 
 
According to the National Department of Health (NDOH, 2011) 45,196 MDR-TB 
and 3,128 XDR-TB cases were confirmed by the National Health Laboratory 
Services (NHLS) between 2004 and 2010. A total 1,296 XDR-TB cases and 
16,821 MDR-TB cases were started on treatment during 2007 to 2010. South 
Africa has the fifth highest burden of MDR-TB in the world (NDOH, 2011). In 
Gauteng 2,030 and 140 patients were started on MDR-TB and XDR-TB 
treatment respectively during the period 2007-2010. These numbers differed 
slightly from the Provincial report (2011) of 1,931 and 106 for MDR and XDR-TB 
respectively. This is the fourth largest number of South African provinces, and the 
largest number was reported in KwaZulu-Natal (NDOH, 2011).  
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As per WHO report (2010), 1.8% of newly diagnosed TB cases and 6.7% of 
previously treated TB cases had MDR-TB. In studies done in South Africa, 6% of 
MDR-TB isolates were found to have XDR-TB (Mlambo, Warren, Poswa, et al., 
2008) and in another study done in Kwazulu-Natal by Gandhi, Moll, Sturm, et al. 
(2006), 39% (185) of confirmed TB cases were MDR-TB and 6% (30) XDR-TB. 
This data confirms the existence of the MDR and XDR-TB challenge in South 
Africa. 
 
2.2           DEMOGRAPHIC PROFILE 
 
2.2.1        AGE 
 
TB cases predominantly occur (approximately 6 million out of 8 million) in the 
economically most productive 15- to 49-year-old age group (Dias-Baptista, et al., 
2008). Patients in age groups older than 14 and younger than 65, were more 
likely to acquire MDR- TB according to Espinal, Laserson, Camacho, et al. (2001) 
and Kliiman, et al.(2009). A median age of 32, 6 years for MDR-TB and a mean 
age of 33 years in XDR-TB were found in studies in Oman and in South Africa 
respectively (Mohammadi, Nassor, Behlim, et al., 2008; Dheda , Shean, Zumla, 
et al., 2010). Other studies in South Africa found a median age of 36 years for 
XDR-TB (Mlambo, et al., 2008) and a median age of 35 years in a study by 
Gandhi et al. (2006) in Kwazulu-Natal. This shows that drug-resistant TB occurs 
mostly in the younger age group. 
 
2.2.2       GENDER 
 
Studies on MDR and XDR-TB showed a higher percentage in males (Espinal, et 
al., 2001; Kliiman, et al., 2009). A WHO report (2010) that looked at data from 
different countries showed that females worldwide had a higher likelihood of 
harboring MDR-TB. However, no association was seen between MDR-TB and 
the sex of the TB patient. In South Africa, although a higher number of male than 
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female MDR-TB cases were reported; female TB cases were 1.2 times more 
likely to harbor MDR-TB strains than male TB cases (WHO, 2010). The study by 
Kliiman et al. (2009) in Estonia showed a six fold increased risk of MDR-TB in 
females younger than 25 years.  
 
2.3          CLINICAL PROFILE 
 
XDR-TB frequently follows TB or MDR-TB treatment and rates of acquisition of 
primarily XDR-TB differ from setting to setting (Dheda, et al., 2010; WHO, 2010). 
Seventy two percent of XDR-TB patients had MDR-TB in a South African study 
by, Dheda, et al. (2010). Kliiman et al. (2009) found that the odds of MDR-TB 
among the previously treated TB patients was 4.11 times (95% CI 2.77 to 6.08) 
than the risk of MDR-TB among patients who never had TB and a higher odds of 
10.54 times (95% CI 5.97 to 6.08) among XDR-TB in the previously treated TB 
patients than the risk of XDR-TB among patients who never had TB. Espinal et 
al. (2001) showed ineffective treatment as a strong predictor of drug resistance. 
Studies in South Africa showed that TB not effectively treated and cured, 
contributes towards drug-resistant TB (Holtz, Lancaster, Laserson, et al., 2006; 
Mlambo, et al., 2008). Prior exposure to anti-TB drugs according to data is a well-
established risk factor for drug resistance, although the contribution of previous 
treatment to outcomes is unclear (Cox, Ford, McDermid, et al., 2010). 
 
It is evident from the epidemiological overlap that a high prevalence of HIV/AIDS 
fuels the TB epidemic; however, the literature is not consistent about HIV as a 
co-factor for MDR or XDR-TB (Dias-Baptista, et al., 2008; WHO, 2010). Some 
studies have found that MDR-TB is not more common among people infected 
with HIV and that HIV infection per se does not appear to be a predisposing 
factor for the development of MDR-TB (Dias-Baptista, et al., 2008). A significant 
association however, was shown in a WHO report (2010) for specific countries. 
For example in Estonia, HIV was found to be an independent predictor of XDR-
TB (Kliiman et al., 2009), however other studies did not show any significant 
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relationship between HIV and M/XDR-TB (Espinal, et al., 2001; Blaas, et al., 
2008). High mortality was reported among HIV co-infected individuals (Gandhi, et 
al., 2006; Migliori, et al., 2007; Farley, et al., 2011).  
 
2.4          TREATMENT OUTCOMES 
 
2.4.1       MDR-TB 
 
From the data of 71 countries, the WHO reported on treatment success in 60% of 
patients overall and contributed low treatment success even in well-resourced 
settings due to a high frequency of death, default and treatment failure, as well as 
many cases reported without definitive outcomes (WHO, 2010). Treatment 
success in studies done ranged from 48% to 66%, death rates were between 7% 
and 12% and default rates 12% to 29% (Dias-Baptista, et al., 2008). In a study 
done by Brust, Gandhi, Carrara, et al. (2010) in KwaZulu-Natal, the success rate 
was 44%, 21% defaulted, mortality rate 18% and the failure rate was high at 
17%. Previous TB treatment was a risk factor for the high treatment failure, HIV 
and males for default and HIV for death (Brust, et al., 2010).  WHO estimated the 
number of MDR-TB deaths excluding those with HIV infection as 97 000. MDR-
TB case fatality in HIV-negative cases was estimated at 26%. There is however 
very little data providing direct measurements of MDR-TB case fatality (WHO, 
2010). The outcomes differed worldwide and factors contributing to poor 
outcomes need further exploration in different settings to plan interventions. 
 
2.4.2        XDR-TB 
 
XDR-TB is found to have worse and poorer clinical outcomes than MDR-TB 
(Migliori, et al., 2007; Jassal, et al., 2009). In Peru 46% (17) were cured, 22% (8) 
died and 30% (11) failed or defaulted treatment (Bonilla, et al., 2008). Successful 
treatment of 60% and 65% was however reported in HIV negative patients 
(Mitnick, et al., 2008; Sotgiu, et al., 2009). It should be noted that these studies 
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are limited by the relatively small sample size included. In another study done in 
Kwazulu-Natal by Dheda, et al. (2010) a high proportion of 36% (62) died. The 
CDC United States reported in 2000 that 64% of patients died (Thaver, et al., 
2006). The largest outbreak of XDR-TB was in KwaZulu-Natal South Africa with a 
mortality rate of 98% (52) amongst HIV-positive patients (Gandhi et al., 2006). 
However, Dheda et al. (2010) did not find HIV to be a predictor of death in XDR-
TB in South Africa. Data suggests that death contributes towards the poorer 
outcomes and interim outcomes could be evaluated to assess the early and late 
impact of deaths.  
 
In a comparative study by Kim et al. (2008) in South Korea, the default rate was 
found to be high (453/1407; 32%), and patients with XDR-TB had lower treatment 
success (29.3% vs. 46.2%; P=0.004) and higher all-cause (49.3 % vs.19.4%; 
P<0.001) and TB-related disease mortality (41.3% vs. 11.8%; P<0.001) than 
other patients with MDR-TB. The presence of XDR-TB significantly affected 
treatment success (odds ratio, 0.23; 95% confidence interval [CI], 0.08–0.64; P= 
0.005), all-cause mortality (hazards ratio, 3.25; 95% CI, 1.91–5.53; P<0.001), 
and TB-related mortality (hazards ratio, 4.45; 95% CI, 2.48–8.00; P< 0.001) on 
multivariate analyses. XDR-TB was found to be the strongest predictor of 
treatment outcome and long term survival.  
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CHAPTER 3 
METHODOLOGY 
 
The methodology for this study was selected on the basis of its aims and 
objectives. In this chapter the following are described: study design, setting, 
period, scope and research tools. 
 
3.1 STUDY DESIGN 
 
This was an analytical cross sectional study based on a retrospective record 
review conducted at Sizwe Hospital in the Gauteng Province.  
 
3.2 STUDY SETTING  
 
The study setting was Sizwe Hospital and all adult patient records for the period 
1st of January 2008 to the 31st of December 2009 were reviewed. Sizwe Hospital 
is a provincial public hospital, situated in the Greater Johannesburg Metropolitan 
Municipal area and is the only Specialised TB Hospital for the entire Gauteng 
Province. The hospital has 266 beds, is responsible for the management of MDR 
and XDR-TB patients, and receives referrals from the six districts in the province, 
as indicated in figure 3.1. The six health districts of Gauteng Province are 
Johannesburg Metropolitan, Ekurhuleni Metropolitan, Tshwane Metropolitan, 
West Rand, Sedibeng and Metsweding Districts. Patients are referred back to the 
District clinics with organized transport for directly observed therapy (DOT) after 
culture conversion and followed up at the hospital outpatient department for 
monitoring and recording. Gauteng Province is the smallest, most densely 
populated province in South Africa, and has the second highest population of 11 
million (almost 25% of the total population of the country).  
 
 
 - 12 -
  
 
Figure 3.1: Gauteng Province 
 
3.3 STUDY SCOPE 
 
The study involved secondary data collected retrospective from the medical 
records of adult MDR and XDR-TB patients admitted in Sizwe Hospital during the 
study period.   
 
3.4 STUDY PERIOD 
 
The study reviewed the relevant records for the two year periods from 1 January 
2008 to 31 December 2009. 
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3.5 STUDY POPULATION AND SAMPLING 
 
The study population was TB patients admitted at Sizwe Hospital. A total of 891 
records for the period 1 January 2008 to 31 December 2009 were reviewed. All 
records were reviewed hence no specific sample size was used. Patients 15 years of 
age or older were included. 
 
3.6 DATA MANAGEMENT  
3.6.1 VARIABLES 
 
The variables measured with their indicators for each objective are listed in the 
table below. 
 
Table 3.1: Objectives and study variables 
Objective   Variables Indicators 
To describe and 
compare  
admission trends. 
Admissions.  No. of MDR and XDR-TB patients 
admitted.  
 
To describe and 
compare 
demographics. 
Demographic profile: 
Age, gender. 
Clinical profile: 
HIV, previous TB 
treatment 
Age (in years). 
Gender (male/female). 
HIV status (pos/neg/unknown). 
Previous TB treatment (yes/no). 
To determine 
changes in 
treatment 
outcomes. 
 
Interim treatment 
outcome. 
 
Treatment   outcome. 
MDR/XDR-TB: 
Death, treatment default, still in 
hospital, transferred out and 
culture conversion. 
Treatment completed, transfer out, 
death, treatment default, treatment 
failure, still on treatment and cured. 
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3.6.2 DATA COLLECTION 
 
Data for this study was collected from the routine medical records including the drug-
resistant TB registers. Data were collected for the following variables: admissions, age, 
gender, HIV status, previous TB treatment, interim treatment outcome and treatment 
outcome. The interim treatment outcome data were collected for the duration of 
hospitalisation and treatment outcome data was as on the 31st of May 2011. Data was 
extracted from the registers and entered in MS Excel spreadsheet. The tool was 
designed for this study (Appendix A). The data were cleaned and quality of data was 
ensured by going back to the records to check for missing information. 
  
3.6.3       DATA ANALYSIS 
 
The data were analysed using EPI-Info software version 3.4.1. The following 
descriptive statistics were reported: 
· For numerical variables (age): Median and interquartile range was used to 
analyse the skewed distribution. 
· For categorical variables (admissions, gender, HIV status, previous TB 
treatment, interim treatment outcome and treatment outcome): the data were 
analysed as proportions and presented in tables and graphs. 
 
Statistical analysis to compare the two years was done using the Mann-Whitney 
U test for the numerical variable and the Chi-square test for the categorical 
variables. The statistical significance was calculated at the 95% confidence level. 
Logistic regression was performed to determine factors influencing death as an 
outcome variable. 
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3.7       ETHICAL CONSIDERATIONS 
 
The protocol for this study was approved by the Human Research Ethics 
Committee (Medical) of the University of the Witwatersrand for approval (see 
appendix B). 
 
Permission to conduct the study and access to medical records at Sizwe 
Hospital was received from the Gauteng Department of Health and Social 
Development (see appendix C). 
 
The study had no potential risk for subjects as the information for this study was 
based on retrospective review of routine collected hospital information. No primary 
data collection was done. The information was extracted anonymously on the data 
collection tool without patient’s identification (such as name and hospital number). A 
separate list coded the name of the patient and was kept by the researcher to ensure 
confidentiality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 16 -
CHAPTER 4 
RESULTS 
 
The main results obtained from the analysis of the study data are described in 
this chapter. Admission trends, demographic characteristics, clinical profiles and 
treatment outcomes of MDR and XDR-TB are presented in this chapter. 
 
4.1      ADMISSION TRENDS 
 
The total number of adult admissions for the period 1 January 2008 to 31 
December 2009 was 891. The number of patients admitted to the hospital during 
2008 and 2009 was 381 and 510 respectively. The adult MDR-TB admissions 
accounted for 95.3% of the total admissions and XDR-TB for 4.7% as illustrated 
in Table 4.1. 
 
Table 4.1:  Comparison of MDR and XDR-TB admissions between 2008 and 
2009. 
Diagnosis Total 2008 2009 p- value 
MDR 849 (95.3%) 364 (95.5%) 485 (95.1%)  
0.75 XDR   42 (4.7%)   17 (4.5%)   25 (4.9%) 
Total 891 (100%) 381 (100%) 510 (100%) 
 
Although there was a 33% increase in MDR-TB and a 47% increase in XDR-TB 
between 2008 and 2009, there was no statistical significant difference between 
the years (Chi-square test, p- value = 0.75). 
 
4.2      DEMOGRAPHIC PROFILE OF PATIENTS 
 
The demographic distribution according to gender and age between the study 
groups was as follows: 
- 17 - 
 
4.2.1     GENDER 
 
Four hundred and ninety seven (55.8%) of the total admissions were males. In 
2008, 56.4% (215) of admissions were males and 43.6% (166) were females, 
resulting in a male to female ratio of 1:0.77. In 2009, 55.3% (282) of the patients 
admitted were males and 44.7% (228) were females resulting in a male to female 
ratio of 1:0.81 as indicated in table 4.2. 
 
Table 4.2:  Gender comparison between 2008 and 2009. 
Gender  Total 2008 2009 p- value 
Female 394 (44.2%) 166 (43.6%) 228 (44.7%)  
0.73 Male 497 (55.8%) 215 (56.4%) 282 (55.3%) 
Total 891 (100%)    381 (100%) 510 (100%) 
 
A slightly higher proportion was noted for female admissions in 2009 compared 
to 2008, but a higher proportion of males was admitted in both years, with no 
significant difference (Chi-square test, p-value = 0.73). 
 
In table 4.3 below, gender in MDR and XDR-TB was compared. A higher 
proportion of males was also diagnosed with both MDR-TB and XDR-TB. The 
proportion of males with XDR-TB was slightly higher compared to males with 
MDR-TB (57.1% vs. 55.7 %), however, this was not statistically significant (Chi-
square test, p-value = 0.85). 
 
Table 4.3: Comparison of gender between MDR and XDR-TB. 
 Gender Total MDR XDR p- value 
Female 394 (44.2%) 376 (44.3%) 18 (42.9%)  
0.85 
 
Male 497 (55.8%) 473 (55.7%) 24 (57.1%) 
Total 891 (100%) 849 (100%) 42 (100%)  
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4.2.2     AGE 
 
The ages ranged from 15 to 79 years. The median age was 36 years overall (IQR 
29-54), with a median age of 35 years (IQR 29-43.5) and 36.5 years (IQR 29-44) 
for 2008 and 2009 respectively (Table 4.4). 
 
Table 4.4: Age comparison between 2008 and 2009 in years. 
Age Total 2008 2009 p-value 
Median (IQR) 36 (29-54) 35 (29-43.5) 36.5 (29-44)  
0.42 Minimum 15 15 15 
Maximum 79 79 76 
 
The median age of 36.5 was higher in 2009 than the 35 of 2008. No significant 
difference however, was found using the Mann Whitney’s test (p-value= 0.42), 
when the median age was compared between the different years. The histogram 
of age in figure 4.1 shows a distribution curve with the majority of patients lying   
in the productive ages between 28 and 32 years. The data is skewed. The test 
for skewness, using D’Agostinos’ test, gave a probability of 0.001. 
 
Figure 4.1: Histogram of age 
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The age comparison between MDR and XDR-TB in table 4.5 shows a bigger 
range for MDR-TB (15-79 years) compared to XDR-TB (18-62 years). The 
median age for MDR and XDR-TB was 36 years (IQR 29-54) and 35 years (IQR 
27-40.5) respectively with no significant difference (Mann Whitney’s test, p-value 
= 0.32).   
 
Table 4.5: Age comparison between MDR and XDR-TB in years.  
Age Total MDR XDR p-value 
Median (IQR) 36 (29-54) 36 (29-44) 35(27- 40.5)  
0.32 Minimum 15 15 18 
Maximum 79 79 62 
 
 
4.3      CLINICAL PROFILE 
 
4.3.1    PREVIOUS TB HISTORY 
 
The majority of patients had a history of previous TB (75.9%), with 295 (77.4%) in 
2008 and 381 (74.7%) in 2009, as reflected in table 4.6. There was an increase 
in the proportion of patients with no previous TB history from 22.6% to 25.3%. 
This difference was however, not statistically significant using the Chi-square test 
(p-value = 0.34). 
 
Table 4.6: History of previous TB in the study groups. 
Previous TB Total 2008 2009 p-value 
No 215 (24.1%) 86 (22.6%) 129 (25.3%)  
0.34 Yes 676 (75.9%) 295 (77.4%) 381 (74.7%) 
Total 891 (100%) 381 (100%) 510 (100%) 
 
Six hundred and thirty six (74.9%) and 40 (95.2%) of MDR and XDR-TB patients 
respectively had a previous history of TB, as outlined in table 4.7. The 33% 
increase between 2008 and 2009 with no previous history, was not significant. 
 - 20 -
There was however, a significant association between diagnosis and previous 
history of TB (Chi-square test, p<0.01). The previous history of TB was 
significantly associated with XDR- TB. 
 
Table 4.7: History of previous TB between MDR and XDR-TB. 
Previous TB Total MDR XDR p-value 
No 215 (24.1%) 213 (25.1%) 2 (4.8%)  
p< 0.01 
 
Yes 676 (75.9%) 636 (74.9%) 40 (95.2%) 
Total   891 (100%) 849 (100%) 42 (100%) 
 
 
Figure 4.2 below illustrates that the majority of patients had a history of previous 
TB with a higher proportion of XDR-TB compared to MDR-TB. 
 
 
 
Figure 4.2: Previous history of TB in MDR and XDR-TB. 
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4.3.2       HIV STATUS 
 
A high proportion of 74.9% (655) of the patients were HIV positive as indicated in 
table 4.8. Two hundred seventy three (73.2%) of the patients were HIV positive in 
2008 and 382 (76.1%) in 2009, however, there was no statistically significant 
difference between the years (Chi-square test, p-value =0.33). 
 
Table 4.8: Comparison of HIV status between 2008 and 2009. 
 HIV status Total 2008 2009 p-value 
Negative 220 (25.1%) 100 (26.8%) 120 (23.9%)  
0.33 Positive 655 (74.9%) 273 (73.2%) 382 (76.1%) 
Total 875 (100%) 373 (100%) 502 (100%) 
 
 
Table 4.9 is a summary of the HIV status in MDR and XDR-TB. A higher 
proportion of XDR-TB patients were HIV positive (78%) compared to the 74.7% 
of MDR-TB HIV positive patients. The difference was not statistically significant 
between the two groups (Chi-square test, p-value = 0.62).  
 
Table 4.9: HIV status in MDR and XDR-TB. 
 HIV status Total MDR XDR p-value 
Negative 220 (25.1%) 211 (25.3%)  9 (22.0%)  
0.62 Positive 655 (74.9%) 623 (74.7%) 32 (78.0%) 
Total 875 (100%) 834 (100%)  41 (100%) 
 
As illustrated in table 4.10, a higher proportion of females (81.5%) compared to 
males (69.5%) were HIV positive, with a significant association between gender 
and HIV status (Chi-square test, p-value <0.0001). A positive HIV status in these 
patients is significantly associated with female gender.  
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Table 4.10: HIV status and gender.   
 HIV status Total Female Male p-value 
Negative 220 (25.1%)   72 (18.5%) 148 (30.5%)  
<0.0001 
 
Positive 655 (74.9%) 317 (81.5%) 338 (69.5%) 
Total 875 (100%) 389 (100%)   486 (100%) 
 
 
4.4      TREATMENT OUTCOME 
 
4.4.1      INTERIM TREATMENT OUTCOME 
 
Interim treatment outcomes for this study were outcomes reported for the 
duration of hospitalisation. Table 4.11 compares the interim treatment outcomes 
between 2008 and 2009 combined for MDR and XDR-TB. High culture 
conversion was achieved. In 2008, 308 (80.8%) had sputum culture conversion, 
with 46 (12.1%) deaths, 13 (3.4%) treatment defaulters, 7 (1.8%) still in hospital 
and 7 (1.8%) transferred out. In 2009, 391 (76.7%) culture converted, 82 (16.1%) 
died, 18 (3.5%) defaulted treatment, 15 (2.9%) were still in hospital and 4 (0.8%) 
were transferred out. Culture conversion decreased in 2009 (76.7% vs. 80.8% in 
2008) mainly as a result of increased death rate (16.1% vs. 12.1%) and more 
patients still in hospital (2.9% vs.1.8%) during 2009. Early deaths result from late 
referrals. There was no significant difference in the interim treatment outcomes 
between the two years (Chi-square test, p-value = 0.20). 
 
Table 4.11: Comparison of interim treatment outcomes between 2008 and 
2009. (combined for MDR and XDR-TB) 
Interim treatment 
outcome 
Total 2008 2009 p-value 
Culture conversion 699 (78.5%) 308 (80.8%) 391 (76.7%) 0.20 
 
 
Death 128 (14.4%)   46 (12.1%)   82 (16.1%) 
Still in hospital 22 (2.5%)  7 (1.8%) 15 (2.9%) 
Treatment default 31 (3.5%)    13 (3.4%) 18 (3.5%) 
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Transfer out 11 (1.2%)  7 (1.8%)  4 (0.8%) 
Total 891 (100%) 381 (100%)   510 (100%) 
  
The interim treatment outcomes of MDR and XDR-TB are compared in table 4.12 
for the study period.  The 79.2% (672) culture conversion for MDR-TB was higher 
compared to the 64.3% (27) of XDR-TB. The possible reasons could be that 
more XDR-TB patients died (26.2%, n=11) compared to the 13.8% (117) of 
MDR-TB patients and 4.8% (2) XDR-TB patients defaulted treatment compared 
to 3.4% (29) MDR-TB patients. No statistical significant difference between the 
interim treatment outcomes of MDR and XDR-TB was found (Chi-square test, p-
value = 0.19). 
 
Table 4.12: Interim treatment outcomes comparison between MDR and 
XDR-TB. 
Interim treatment 
outcome 
Total MDR XDR  p-value 
Culture conversion 699 (78.5%) 672 (79.2%) 27 (64.3%)  
 
0.19 
 
Death 128 (14.4%) 117 (13.8%) 11 (26.2%) 
Still in hospital 22 (2.5%) 21 (2.5%) 1 (2.4%) 
Treatment default 31 (3.5%) 29 (3.4%) 2 (4.8%) 
Transfer out 11 (1.2%) 10 (1.2%) 1 (2.4%) 
Total 891 (100%) 849 (100%) 42 (100%) 
 
The interim treatment outcomes for MDR and XDR-TB in 2008 are illustrated in 
figures 4.3 and 4.4. Culture conversion for MDR-TB (364) was higher than XDR-
TB (17) and was 81.3% (296) and 70.6% (12) respectively. The other outcomes 
for MDR-TB were 11.5% (42) deaths, 3.6% (13) treatment default, 1.9% (7) still in 
hospital and 1.7% (6) transferred out. XDR-TB patients had 23.6% (4) deaths, 
5.8% (1) transfer out and no patients defaulted treatment or were sill in hospital. 
The results were an indication of interim treatment success achieved. 
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Figure 4.3: Interim outcomes for MDR-TB in 2008. 
 
 
Figure 4.4: Interim outcomes for XDR-TB in 2008 
 
Figures 4.5 and 4.6 indicate the interim treatment outcomes for MDR (485) and 
XDR-TB (25) in 2009. Culture conversion was 77.5% (376) and 60% (15) for 
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MDR-TB and XDR-TB respectively. Again, culture conversion was higher in 
MDR-TB and deaths were more in XDR-TB, similar to the findings of 2008. 
 
 
Figure 4.5: Interim treatment outcomes for MDR-TB in 2009. 
 
 
 
Figure 4.6: Interim treatment outcomes for XDR-TB in 2009. 
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The difference in the interim treatment outcomes between HIV positive and HIV 
negative patients is shown in table 4.13. Eighty four percent (185) HIV negative 
compared to 76.9% (504) HIV positive patients achieved culture conversion. 
More [15.9% (104)] HIV positive, than the 9.5% (21) HIV negative patients died. 
Three percent (20) and 4.1% (9) HIV positive and HIV negative patients defaulted 
treatment respectively.  Although culture conversion is higher in the HIV negative 
patients and the death rate and still in hospital  higher in HIV positive patients, no 
statistically significant difference was observed between the two groups for the 
study period (Chi-square test. p-value = 0.05). 
 
Table 4.13: Comparison of interim treatment outcomes and HIV status. 
Interim treatment 
outcome 
Total HIV negative HIV positive  p-value 
Culture conversion 689 (78.7%) 185 (84.1%) 504 (76.9%)  
 
 0.05 
Death 125 (14.3%)     21 (9.5%) 104 (15.9%) 
Still in hospital 22 (2.5%)  2 (0.9%) 20 (3.1%) 
Treatment default 29 (3.3%)  9 (4.1%) 20 (3.1%) 
Transfer out 10 (1.1%)   3 (1.4%)  7 (1.1%) 
Total 875 (100%) 220 (100%) 655 (100%) 
 
The interim treatment outcomes for HIV positive MDR and XDR -TB patients is 
summarised in table 4.14. Seventy eight percent (486) HIV positive MDR-TB 
patients culture converted compared to 56.3% (18) HIV positive XDR-TB 
patients.  Although higher culture conversion was achieved in HIV positive MDR- 
TB patients, deaths (31.3%), treatment default (6.3%) and still in hospital (3.1%) 
were higher in HIV positive XDR -TB patients. The difference in interim treatment 
outcomes between HIV positive MDR and XDR- TB HIV positive patients was not 
significant (Chi-square test, p-value = 0.05). 
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Table 4.14: Interim treatment outcomes in HIV positive patients compared 
between MDR and XDR-TB. 
Interim treatment 
outcome 
Total MDR XDR p-value 
Culture conversion 504 (76.9%) 486 (78%) 18 (56.3%)  
 
 0.05 
Death 104 (15.9%)     94 (15.1%) 10 (31.3%) 
Still in hospital 20 (3.1%) 19 (3%) 1 (3.1%) 
Treatment default 20 (3.1%)   18 (2.9%) 2 (6.3%) 
Transfer out 7 (1.1%)    6 (1.0%) 1 (3.1%) 
Total 655 (100%) 623 (100%) 32 (100%) 
 
 
4.4.2        TREATMENT OUTCOME 
 
Treatment outcome for this study was for all adult MDR and XDR-TB patients 
registered in 2008 and 2009 as at the end of May 2011. Cure was achieved only 
when a patient had five consecutive monthly negative sputum culture results 
documented in the last twelve months. For the total study population, a low cure 
rate of 2.4% (21) was achieved, with treatment completion of 25.7% (229). The 
high number of patients still on treatment [21.5%, (n=192)], as a result of the long 
period of treatment for 18- 24 months, contributed to the low success rate of 
28.1% (cure and completed). Deaths were 22% (196) and treatment default 
20.8% (158). Treatment failure was low at 3.1% (28). A comparison between the 
treatment outcomes for 2008 and 2009 is illustrated in table 4.15. 
 
Cure was low at 2.1% (8) and 2.5% (13) in 2008 and 2009 respectively. 
Treatment completion was higher at 42% (160) in 2008 than the 13.5% (69) in 
2009. The treatment success rate (cure and completion) therefore, was 44.1% in 
2008 and 16% in 2009. Nineteen percent (74) died in 2008 and 23. 9% (122) 
died in 2009. Treatment failure was low, 2.6 % (10) and 3.5% (18) in 2008 and 
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2009 respectively with high treatment default of 22.6% (86) in 2008 and 19.4 % 
(99) treatment default in 2009. More deaths and more patients still on treatment 
were in the 2009 cohort, and this was statistically significant (Chi-square test, p-
value <0.01). 
 
 
Table 4.15: Comparison of treatment outcomes between 2008 and 2009. 
Treatment outcome Total 2008 2009 p-value 
Cure 21 (2.4%)  8 (2.1%) 13 (2.5%)  
 
 
<0.01 
Death 196 (22%)  74 (19.4%) 122 (23.9%) 
Still on treatment 192 (21.5%) 22 (5.8%) 170 (33.3%) 
Treatment completed 229 (25.7%)  160 (42%)   69 (13.5%) 
Treatment default 185 (20.8%)   86 (22.6%)   99 (19.4%) 
Treatment failure 28 (3.1%)  10 (2.6%) 18 (3.5%) 
Transfer out 40 (4.5%)  21 (5.5%) 19 (3.7%) 
Total 891 (100%) 381 (100%) 510 (100%) 
 
 
Table 4.16 compares the treatment outcomes between HIV positive and HIV 
negative patients. Four percent (9) HIV negative patients were cured compared 
to 1, 8% (12) HIV positive patients. Higher cure and treatment completion rates 
were achieved in the HIV negative patients. Deaths and treatment default was 
higher in the HIV positive patients, with no significant difference. (Chi-square test, 
p-value = 0.05)` 
 
Table 4.16: Treatment outcomes compared with HIV status. 
Treatment outcome Total HIV negative HIV positive p-value 
Cure    21 (2.4%) 9 (4.1%) 12 (1.8%)  
0.05 
 
Death 192 (21.9%)    33 (15.0%) 159 (24.3%) 
Still on treatment 190 (21.7%) 54 (24.5%) 136 (20.8%) 
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Treatment completed 223 (25.5%) 61 (27.7%) 162 (24.7%)  
 Treatment default 183 (20.9%)    44 (20%) 139 (21.2%) 
Treatment failure 28 (3.2%)      7 (3.2%)    21 (3.2%) 
Transfer out 38 (4.3%)    12 (5.5%)    26 (4.0%) 
Total 875 (100%)  220 (100%)  655 (100%) 
 
Treatment outcomes for male and female are shown in table 4.17. The deaths, 
treatment completion and transfer outs were slightly higher in females and still on 
treatment and treatment default were higher in males. The difference was not 
statistically significant (Chi square test, p-value =0.58). 
 
Table 4.17: Comparison of treatment outcomes and gender. 
Treatment outcome Total Female Male p-value 
Cure 21 (2.4%) 9 (2.3%) 12 (2.4%)  
 
 
0.58 
Death  196 (22%)  91 (23.1%) 105 (21.1%) 
Still on treatment 192 (21.5%) 74 (18.8%) 118 (23.7%) 
Treatment completed 229 (25.7%) 107 (27.2%)  122 (24.5) 
Treatment default 185 (20.8%)   80 (20.3%) 105 (21.1%) 
Treatment failure 28 (3.1%)   12 (3%) 16 (3.2%) 
Transfer out 40 (4.5%)   21 (5.3%) 19 (3.8%) 
Total  891 (100%) 394 (100%)   497 (100%) 
 
As shown in table 4.18, the treatment outcomes for MDR-TB were 2.5% (21) 
cure, 26.7% (227) treatment completed, 21.3% (181) deaths, 21% (178) still on 
treatment, treatment default 21 % (178), treatment failure 3.2 % (27) and 4.4% 
(37) were transfer out. 
  
The treatment outcomes for XDR-TB were 0% cure, 4.8% (2) treatment 
completed, 35.7% (15) deaths, 33.3% (14) still on treatment, 16.7% (7) treatment 
default, 2.4% (1) treatment failure and 7.1% (3) transfer out. Cure, treatment 
 - 30 -
completion, treatment default and treatment failures were higher in MDR-TB. The 
death rate and still on treatment were, however, higher in XDR-TB compared to 
MDR-TB and this was statistically significant (Chi-square test, p-value<0.01). 
Death and still on treatment was significantly associated with XDR-TB. 
 
Table 4.18: Treatment outcomes comparison in MDR and XDR-TB. 
Treatment outcome Total MDR  
 
XDR p-value 
Cure 21 (2.4%) 21 (2.5%)     0 (0%)  
 
 
<0.01 
 
 
 
 
Death 196 (22%) 181 (21.3%) 15 (35.7%) 
Still on treatment 192 (21.5%)   178 (21%) 14 (33.3%) 
Treatment completed 229 (25.7%) 227 (26.7%) 2 (4.8%) 
Treatment default 185 (20.8%)   178 (21%)  7 (16.7%) 
Treatment failure 28 (3.1%) 27 (3.2%) 1 (2.4%) 
Transfer out 40 (4.5%) 37 (4.4%) 3 (7.1%) 
Total 891 (100%) 849 (100%) 42 (100%) 
 
 
The treatment outcomes for MDR-TB and XDR-TB in 2008 are illustrated in 
figures 4.7 and 4.8 respectively. MDR-TB outcomes were as follows: 2.2% (8) 
cure, 43.4% (158) treatment completed, 18.4% (67) deaths, 23.4% (85) treatment 
default, 2.8% (10) treatment failure, 4.9% (18) transfer out and 4.9% (18) still on 
treatment. No XDR-TB patients were cured. Other outcomes were 11.8% (2) 
treatment completed, 41.2% (7) death, 5.9% (1) treatment default, 17.6% (3) 
transfer out and 23.5% (4) still on treatment. The successful treatment 
completion rate achieved for MDR-TB was 45.6% (166) and low for of XDR-TB 
[11.8% (n=2)]. The death and defaulter rates were high for MDR and XDR-TB.  
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Figure 4.7 MDR-TB treatment outcomes 2008. 
 
 
 
Figure 4.8 XDR-TB treatment outcomes 2008. 
 
The treatment outcomes for MDR-TB and XDR-TB in 2009 are shown in figures 
4.9 and 4.10 respectively. Thirty three percent (160) MDR-TB patients and 40% 
(10) XDR-TB patients were still on treatment due to the duration of treatment. 
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Therefore no XDR-TB patients and only 2.7% (13) MDR-TB patients were cured, 
no XDR-TB patients and only 14.2% (69) MDR-TB patients completed treatment. 
Other outcomes for MDR-TB were 23.5% (114) deaths, 19.2% (93) treatment 
default, 3.9% (19) transfer out and 3.9% (19) treatment failure. 24% (6) of XDR-
TB patients defaulted treatment, 32% (8) died and 45 (1) failed treatment. 
 
 
Figure 4.9 MDR-TB treatment outcomes 2009. 
 
 
Figure 4.10 XDR-TB treatment outcomes 2009. 
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The treatment outcomes in MDR and XDR-TB HIV positive patients are 
summarised in table 4.19. In the HIV positive patients, the MDR-TB treatment 
outcomes were as follows: 1.9% (12) was cured, 26% (162) completed treatment, 
23.3% (145) died, 20.2% (126) were still on treatment, 21.5% (134) defaulted 
treatment, 3.2% (20) failed treatment and 3.9% (24) were transferred out. In the 
HIV positive XDR-TB patients, none were cured or completed treatment. Other 
treatment outcomes were 43.8% (14) deaths, 31.3% (10) still on treatment, 
15.6% (5) treatment default, 3.1% (1) treatment failure and 6.3% (2) transfer out.  
 
Higher cure and treatment completion was achieved in MDR-TB HIV positive 
patients compared to XDR-TB HIV patients, despite the higher treatment default 
in MDR-TB HIV positive patients. Deaths and still on treatment were higher 
amongst XDR-TB HIV patients, with statistical significance (Chi-square test, p-
value < 0.01). Death and still on treatment was significantly associated with HIV 
positive XDR-TB patients. 
 
Table 4.19: Treatment outcomes comparison in HIV positive patients 
between MDR and XDR-TB. 
Treatment outcome Total MDR XDR p-value 
Cure 12 (1.8%) 12 (1.9%) 0 (0.0%)  
 
 
< 0.01 
Death 159 (24.3%) 145 (23.3%) 14 (43.8%) 
Still on treatment 136 (20.8%) 126 (20.2%) 10 (31.3%) 
Treatment completed 162 (24.7%) 162 (26.0%) 0 (0.0%) 
Treatment default 139 (21.2%) 134 (21.5%)   5 (15.6%) 
Treatment failure 21 (3.2%) 20 (3.2%) 1 (3.1%) 
Transfer out   26 (4.0%) 24 (3.9%) 2 (6.3%) 
Total 655 (100%) 623 (100%) 32 (100%) 
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Logistic regression was done to determine the factors influencing death as an 
outcome variable as indicated in table 4.20. The following variables were tested 
for the model: age, gender, diagnosis, HIV status and previous history of TB. The 
model was significant for age (p<0.02), diagnosis (p<0.03) and HIV status (p< 
0.04). Age, diagnosis and HIV were significantly associated with death (p<0.05). 
The adjusted odds ratio was 0.15 (95% CI of 0.07 to 0.30) which was statistically 
significant (p-value<0.01).  
 
Table 4.20: Logistic regression for factors influencing death as an outcome 
variable.  
Term omitted Odds ratio 95% Confidence Interval p-value 
Age 1.02 1.00-1.03 <0.01 
Diagnosis 0.46 0.23-0.89 0.02 
Gender 1.16 0.83-1.62 0.37 
HIV 0.55 0.36-0.83 0.03 
Previous TB 1.14 0.78-1.66 0.49 
 
The logistic regression performed for MDR-TB patients gave an odds ratio of  
0.12 (95% CI 0.05-0.24; p<0.01) which was statistically significant. However, it 
was not possible to perform a logistic regression separately for XDR-TB patients 
due to the small number.   
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CHAPTER 5  
DISCUSSION 
 
In this chapter, the results obtained from the analysis of the data are discussed 
with reference to other published studies. The limitations of the study are listed. 
Conclusions are drawn and relevant recommendations and suggestions for future 
research are made based on the findings of the study. 
 
5.1 INTRODUCTION 
 
This study was done in order to describe and compare the admission trends and 
treatment outcomes of MDR and XDR-TB at Sizwe Hospital in Gauteng Province 
during the study period 1st of January 2008 to 31st of December 2009. Limited 
studies have been conducted on MDR and XDR-TB treatment outcomes in South 
Africa and risk factors such as the impact of HIV and outcomes of MDR-TB 
treatment, have not been well described (Farley, et al., 2011). This information is 
needed to plan and strengthen the management of MDR and XDR-TB.  
 
5.2 ADMISSION TRENDS 
 
Out of the total study population of 891 admissions, 95.3% were MDR-TB. There 
was an increase in both MDR-TB and XDR-TB admissions between 2008 and 
2009. Previous studies have cited factors contributing to an increase in MDR-TB 
as poverty, poor drug compliance and HIV co-infection (Thaver, et al., 2006). The 
reasons for increased numbers of XDR-TB could presumably be the high number 
of MDR-TB defaulters, high HIV prevalence, inadequate regimens, non 
adherence to TB treatment and delay in case detection (Mlambo, et al., 2008; 
Jassal & Bishai, 2009). Increasing numbers of MDR and XDR-TB indicate a 
failing TB control programme and necessitate a comprehensive, integrated and 
universal approach to address poverty, HIV prevention and care as well as early 
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case detection and holding, in order to reverse the current trends of MDR and 
XDR-TB. 
 
5.3 DEMOGRAPHIC PROFILE OF PATIENTS 
 
5.3.1  GENDER 
 
The higher proportion of male admissions found in this study for both study 
groups, correlated with the findings of other studies (Espinal et al., 2001; Kliiman, 
et al., 2009). The proportion of MDR-TB males (55.7%) in this study was much 
lower than 65.4% found in a previous study done by Njaramba and Naidoo 
(2007), indicating an increase in the proportion of females with MDR-TB over the 
years. However, there was no significant difference between genders in terms of 
admissions to hospital.   
 
5.3.2 AGE 
 
The majority of patients were in the age group of 28-32 years in this study; this 
was lower than the 35-54 age group in the study by Kliiman, et al. (2009) in 
Estonia but within the age group of 15-44 years in a study by Anderson, 
Laurenson, Blatchford, et al. (2009) in Scotland. The median age for MDR-TB of 
36 years correlated with another South African study by Farley, et al. (2011), but 
was higher than the finding in the study by Mohammadi et al. (2008) of 32.6 
years in Oman. A median age of 35 years for XDR-TB was also shown by 
another study by Gandhi et al. (2006) in KwaZulu-Natal and was lower than the 
36 years shown earlier in South Africa by Mlambo et al. (2008) but higher than 
the median age in another South African study (Dheda, et al., 2010). Although 
MDR and XDR-TB affects all age groups, the majority are in the productive age 
group. This has a huge socio-economic impact on families.      
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5.4 CLINICAL PROFILE 
 
5.4.1  PREVIOUS TB HISTORY 
 
The analysis of study data showed that the majority of patients previously 
received TB treatment (75.9%) which indicates that ineffective TB management 
contribute towards drug resistance. Previous treatment was found to be a 
predictor of resistance in a study by Frieden, Sterling, Pablos-Mendez et al. 
(1993). A higher proportion of patients with XDR-TB (95.2%) than MDR-TB 
(74.9%) had a previous history and XDR-TB was significantly (P<0.01) 
associated with previous TB treatment in this study.  Kliman, et al. (2009) found a 
higher association between XDR-TB and previously treated patients than for 
MDR-TB.  Effective TB and MDR-TB management is therefore critical to prevent 
XDR-TB as studies in SA showed that TB not effectively treated and cured 
contributes towards development of drug resistance (Holtz, et al., 2006; Mlambo, 
et al., 2008).  
 
TB drug resistance occurs in patients as a result of inadequate therapy (acquired 
resistance) or by infection with a drug-resistant strain (primary resistance) 
(Andrews, Shah, Gandhi, et al., 2007). Although there was an insignificant 
decrease in the history of previous TB treatment, the increase in primary 
resistance is a concern and indicates transmission of the disease in the 
community, which could be as a result of late diagnosis. Health education and 
strategies to improve infection control in the community need urgent attention.   
 
5.4.2  HIV STATUS 
 
A high proportion (74.9%) of the study population was HIV infected with an 
increase in the proportion of HIV infected patients for the study period. The HIV 
prevalence differs from country to country. Previous studies done in South Africa 
showed 80% co-infection rate (Brust, et al., 2011), 47%  in a study by Dheda, et 
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al. ( 2010) and 100% of patients tested in a study conducted in KwaZulu-Natal 
(Gandhi, et al., 2006), contrary to the 0% in a study done by Mitnick et al. (2008) 
in Peru. The findings of HIV as an independent risk factor are not consistent. 
Kliiman, et al. (2009) found HIV as an independent risk factor for XDR-TB, 
whereas other studies did not find a significant association between HIV and drug 
resistance (Espinal, et al., 2001; Blaas et al., 2008). A significant association 
(p<0.0001) between HIV positive status and female gender (81%) was found in 
this study. The high HIV proportion found among MDR and XDR-TB patients in 
this study necessitates integration of treatment for drug-resistant TB and 
HIV/AIDS and justifies the current hospital policy for all HIV positive patients to 
receive antiretroviral therapy (ARV).   
 
5.5 TREATMENT OUTCOME 
 
5.5.1        INTERIM TREATMENT OUTCOME 
 
High sputum culture conversion was achieved where patients converted from 
positive to negative  in hospital, a very important finding indicating early success, 
similar to findings in other studies in South Africa and Southern Africa (Holtz, 
Sternberg, Kammerer, et al., 2006; Seung, Omatayo, Keshavjee, et al., 2009; 
Brust, Lygizos, Chaiyachati, et al., 2011). The MDR-TB culture conversion rate of 
79.2% is much higher than the 41.9% achieved in a previous study done in the 
hospital by Njaramba, et al. (2007). Culture conversion in XDR-TB of 64.3% 
correlates with a 67% culture conversion rate achieved in a study by Mitnick et al. 
(2008) in Peru. However, a lower culture conversion for XDR-TB (19%) was 
reported by Dheda et al. (2010) in South Africa. A higher conversion rate as 
shown at Sizwe Hospital might have been due to the introduction of moxifloxacin. 
Similar to the study by Brust et al. (2011) in Tugela Ferry, KwaZulu-Natal, no 
difference was found in the culture conversion between HIV negative and HIV 
positive patients and the status therefore should have no impact on interim 
treatment outcomes.  
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Culture conversion is an important interim indicator of treatment success in TB 
management. However, late referrals of patients are among the reasons for early 
deaths in hospital. Therefore earlier detection is needed to improve outcomes 
through the use of new rapid diagnostic tests. Low treatment default rate in the 
intensive treatment phase could be as a result of the in hospital monitoring where 
comprehensive care, treatment under supervision and support is effectively 
provided. 
  
5.5.2        TREATMENT OUTCOME 
 
5.5.2.1      CURE AND TREATMENT COMPLETION  
 
Patients are discharged from hospital to their respective clinics and provided with 
hospital transport. The clinics are then responsible for the continuation of 
treatment, monitoring of progress and transport arrangements for patients follow 
up at the hospital. Patient culture results from the clinics are needed for recording 
thereof in the hospital drug resistant register to report treatment outcomes. 
  
The measure of treatment success is cure and treatment completion according to 
National Policy. Cure is achieved when five consecutive negative cultures are 
obtained in the last year of treatment. Treatment completed lack bacteriologic 
results of sputum culture and therefore does not meet the definition of cure. The 
cure rates were low compared to other studies (Dias-Baptista, et al., 2008; Brust, 
et al., 2010). This could have been due to unavailable sputum culture results 
from the clinics as a result of system failure. Culture results were entered into the 
hospital register as patients are followed up at the hospital. The decrease in 
treatment completion in 2009 was mainly as a result of the significant (p-
value<0.01) increase in deaths and the high proportion of patients still on 
treatment in 2009. Because of the long period of treatment with at least 18 
months following culture conversion, it was expected that some 2009 patients 
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would still be on treatment as a result of data collection as on the 31st of May 
2011.  
  
The successful treatment completion rate (cure and treatment completed as a 
proportion of the total cases) of 45.6% achieved for MDR-TB in 2008 was higher 
than the 11.8% for XDR-TB in 2008 and MDR-TB (16.9%) in 2009. A similar 
finding of 44% MDR-TB success was reported by Brust et al. (2010) from a study 
done in KwaZulu-Natal. Generally studies reported poor treatment outcomes for 
MDR-TB (Schaaf, et al., 2001; Dias -Baptista, et al., 2008) and worse outcomes 
in XDR-TB (Gandhi, et al., 2006; Migliori, et al., 2007; Kim, et al., 2008; Jassal, et 
al., 2009). MDR-TB was not found to be a predictor of poor treatment outcome 
(Solomon, Periman, Friedman, et al., 1995), however, XDR-TB was found to be a 
strong predictor of poor treatment outcome (Kim, et al., 2008). The WHO 
reported 60% success in MDR-TB and stated reasons for poor success as 
deaths, defaulters and treatment failure (WHO, 2010). 
 
5.5.2.2         TREATMENT DEFAULT  
 
One out of five patients defaulted treatment. Factors associated with treatment 
default revealed in the study by Holtz et al. (2006) were, the use of alcohol, 
smoking of marijuana or mandrax, being born outside of South Africa, spending 
time in prison during treatment, not owning a radio, having an unsatisfactory 
opinion of the HCW’s and changing residence during treatment. These factors 
could have contributed to the high default rate in this study. Patients, however, 
may have died as Holtz et al. (2006) found in their study, a significant mortality 
amongst MDR-TB patients thought to have defaulted. Treatment default of XDR-
TB patients (16.7%) was lower than the 32% reported in the study by Kim, et al. 
(2008) in South Korea and this could be due to the fact that patients are 
hospitalised longer. Of concern is the increased defaulter rate from 3.5% to 
20.8% after discharge from hospital. This is probably due to the long duration of 
treatment, but also indicates a failing community DOT system which is a major 
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concern especially in the light of the low success rate of 44% following the 
discharge of patients compared to the 78.5% culture conversion rate achieved 
during hospitalisation.  
 
The findings of the study have severe implications regarding the implementation 
of the National Decentralization Policy (NDOH, 2011). The purpose of the policy 
is to provide community MDR-TB care the policy provides for smear negative 
patients to be treated in the community and for shorter hospital stay until smear 
conversion. Admission of all MDR and XDR-TB cases until culture conversion is 
current hospital policy. Management of MDR-TB in decentralized sites is also 
recommended. Implementation within a challenged system might result in worse 
outcomes in future  
 
5.5.5.3           MORTALITY            
 
The deaths were slightly higher in females, but gender had no impact on 
treatment outcome. Mortality in this study was significantly higher (p-value<0.01) 
in XDR-TB compared to MDR-TB (35.7% vs. 21.35%) and correlated with the 
finding of 36% deaths in the study by Dheda et al. (2010) in South Africa. HIV 
and age were other risk factors in this study significantly associated (p-
value<0.05) with death. HIV, however, was not shown to be a predictor of death 
in XDR-TB in the study by Dheda et al. (2010).  Although the number of deaths in 
this study was higher in HIV positive patients, no significant difference (p-
value=0.05) was noted in treatment outcomes similar to the study by Dheda et al. 
(2010). 
 
5.6      LIMITATIONS OF THE STUDY 
 
The following limitations experienced in conducting this study were:  
v Culture results not available from the clinics resulted in defining patients as 
treatment completed and not cured. This seems to be a major problem that 
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has to be addressed.   
v Final treatment outcomes not available, as a result of treatment continued for 
longer than two years for some patients in 2008 and for many of the patients who 
started therapy in 2009 due to the fact that they were still on treatment at the time 
of data collection as on 31st May 2011, limited comparative analysis between the 
two years for treatment outcomes.   
   
5.8       CONCLUSIONS  
 
The main conclusions from the study are as follows:  
· The co-infection rate is high and warrants comprehensive integrated 
HIV/AIDS care.  
· The high proportion of patients with previous TB reflects ineffective TB 
management and non adherence to treatment in the community.  
· High culture conversion is an indication of early treatment success 
achieved with in hospital care.  
· Low treatment success following discharge has severe implications for a 
decentralized approach within a challenged system.  
· High default and death rates might indicate a failing community TB control 
programme. 
 
5.8      RECOMMENDATIONS 
 
5.8.1      FOLLOW-UP 
 
In line with findings documented earlier, the following recommendations are put 
forward to improve effective management and control of MDR and XDR-TB and 
to improve outcomes in future. Corrective measures are needed to improve the 
system failure to collect and record culture results at the clinics. The electronic 
drug register to link with the laboratory for culture results and to provide treatment 
outcome results. These results to be utilized as a management tool for 
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monitoring and planning of drug-resistant TB. Data collection tool to be 
implemented for routine collection of data to assist with treatment outcome 
analysis.  A comprehensive and integrated approach to combat MDR and XDR-
TB is essential, which include increased awareness and education, integrated 
HIV/TB care and support, the provision of ARV, new technology rapid testing for 
early diagnosis, social support and patients follow up at clinics following 
discharge. The TB control programme needs to be strengthened from early 
detection to case holding, to prevent further drug resistance. Community infection 
control practices needs to be developed through health education. Hospitalisation 
until culture conversion is recommended to sustain early success as well as 
hospital follow up visits until systems are in place. Specialized outreach, training 
and support are recommended to strengthen and ensure community MDR-TB 
care following discharge. Availability of drugs including ARV’s and DOT care is 
requirements for community care. 
 
It is evident that systems need to be put in place to improve strengthen 
community care and support to improve on treatment outcomes. 
 
5.8.2      FUTURE RESEARCH AND DISSEMENATION  
 
Based on findings of this study, the researcher would like to suggest the following 
future studies: 
(a) There is a need to conduct a study to identify risk factors associated with            
defaulting of treatment.  
(b) A  follow up study is needed after treatment completion of the 2009 cohort 
for comparative analysis. 
(c)  Research is needed to further explore and identify risk factors contributing 
to the high mortality rate. 
 
The findings will be communicated through a formal presentation to the hospital 
staff and the Provincial TB Control Programme, the National Department of 
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Health and other specialized TB hospitals in South Africa to assist with future 
planning. The results will also be presented in a local conference and published 
in a peer review.  
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